Published in Gastroenterology Week, June 14th, 2010
"Groups 1-5 (n=6) were intratumorally injected with 14.8 MBq of P-32-CP and sacrificed at 2, 24, 48, 72, and 168 hours, respectively. Groups 6-11 (n=9) received injections of 3.7, 7.4, 14.8, 18.5, 29.6, and 0 MBq of P-32-CP, respectively, and the tumor volume on body surface was measured daily....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.